Clinical application of pharmacogenetics: focusing on practical issues

被引:10
作者
Chang, Matthew T. [1 ,2 ]
McCarthy, Jeanette J. [3 ,4 ]
Shin, Jaekyu [5 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Therapeut Sci, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Div Med Genet, San Francisco, CA 94143 USA
[4] Duke Univ, Dept Community & Family Med, Durham, NC USA
[5] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA
关键词
clinical applications; pharmacogenetics; PharmGKB; IMPLEMENTATION CONSORTIUM GUIDELINES; S-METHYLTRANSFERASE PHARMACOGENETICS; TRANSPORTER GENE ABCB1; CYP2C19; GENOTYPE; B GENOTYPE; ASSOCIATION; THERAPY; UPDATE; HYPERSENSITIVITY; POLYMORPHISMS;
D O I
10.2217/pgs.15.112
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent large-scale genetic-based studies have transformed the field of pharmacogenetics to identify, characterize and leverage genetic information to inform patient care. Genetic testing can be used to alter drug selection, optimize drug dosing and prevent unnecessary adverse events. As precision medicine becomes the mainstay in the clinic, it becomes critical for clinicians to utilize pharmacogenetics to guide patient care. One primary challenge is identifying patients where genetic tests that can potentially impact patient care. To address this challenge, our review highlights many practical issues clinicians may encounter: identifying candidate patients and clinical laboratories for pharmacogenetic testing, selecting highly curated resources to help asses test validity, reimbursing costs of pharmacogenetic tests, and interpreting of pharmacogenetic test results.
引用
收藏
页码:1733 / 1741
页数:9
相关论文
共 27 条
[1]   Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America [J].
Aberg, Judith A. ;
Kaplan, Jonathan E. ;
Libman, Howard ;
Emmanuel, Patricia ;
Anderson, Jean R. ;
Stone, Valerie E. ;
Oleske, James M. ;
Currier, Judith S. ;
Gallant, Joel E. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) :651-681
[2]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[3]   Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question [J].
Cavallari, L. H. ;
Nutescu, E. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (01) :22-24
[4]   Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].
Fleischmann, Roy ;
Kremer, Joel ;
Cush, John ;
Schulze-Koops, Hendrik ;
Connell, Carol A. ;
Bradley, John D. ;
Gruben, David ;
Wallenstein, Gene V. ;
Zwillich, Samuel H. ;
Kanik, Keith S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507
[5]   Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation [J].
Flume, Patrick A. ;
Liou, Theodore G. ;
Borowitz, Drucy S. ;
Li, Haihong ;
Yen, Karl ;
Ordonez, Claudia L. ;
Geller, David E. .
CHEST, 2012, 142 (03) :718-724
[6]   Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions - A Meta-Analysis [J].
Hakkarainen, Katja M. ;
Hedna, Khadidja ;
Petzold, Max ;
Hagg, Staffan .
PLOS ONE, 2012, 7 (03)
[7]   Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing [J].
Hershfield, M. S. ;
Callaghan, J. T. ;
Tassaneeyakul, W. ;
Mushiroda, T. ;
Thorn, C. F. ;
Klein, T. E. ;
Lee, M. T. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) :153-158
[8]   Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir [J].
Hetherington, S ;
McGuirk, S ;
Powell, G ;
Cutrell, A ;
Naderer, O ;
Spreen, B ;
Lafon, S ;
Pearce, G ;
Steel, H .
CLINICAL THERAPEUTICS, 2001, 23 (10) :1603-1614
[9]   Insurance Coverage Policies for Personalized Medicine [J].
Hresko, Andrew ;
Haga, Susanne B. .
JOURNAL OF PERSONALIZED MEDICINE, 2012, 2 (04) :201-216
[10]   Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing [J].
Johnson, J. A. ;
Gong, L. ;
Whirl-Carrillo, M. ;
Gage, B. F. ;
Scott, S. A. ;
Stein, C. M. ;
Anderson, J. L. ;
Kimmel, S. E. ;
Lee, M. T. M. ;
Pirmohamed, M. ;
Wadelius, M. ;
Klein, T. E. ;
Altman, R. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) :625-629